Press release
Renal Cell Carcinoma Pipeline Outlook, Clinical Trials and Emerging Drugs 2024 (Updated)
Renal cell carcinoma Pipeline
Key Takeaways from the Renal Cell Carcinoma Pipeline Report
• DelveInsight's Renal Cell Carcinoma pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
• The leading companies working in the Renal Cell Carcinoma Market include AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc., X4 pharmaceuticals, and others.
• Promising Renal Cell Carcinoma Pipeline Therapies in the various stages of development include Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, and others.
• April 2024: Ipsen- The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in real-life clinical setting in 1st line treatment.
• April 2024: Bristol-Myers Squibb- This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
Request a sample and discover the recent advances in Renal Cell Carcinoma Treatment Drugs @ Renal Cell Carcinoma Pipeline Report- https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Renal Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Renal Cell Carcinoma Overview
Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth.
Find out more about Renal Cell Carcinoma Treatment Landscape @ Drugs for Renal Cell Carcinoma Treatment- https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Renal Cell Carcinoma Emerging Drugs Profile
• CM082: Betta Pharmaceuticals
• TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• IPI-549: Infinity Pharmaceuticals
• CMN-001: ColImmune
Renal Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for Renal Cell Carcinoma. The Renal Cell Carcinoma companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.
DelveInsight's Renal Cell Carcinoma pipeline report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
• Product Type
Learn more about the emerging Renal Cell Carcinoma Pipeline Therapies @ Renal Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Renal Cell Carcinoma Pipeline Report
• Coverage- Global
• Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc., X4 pharmaceuticals, and others.
• Renal Cell Carcinoma Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, and others.
Dive deep into rich insights for new drugs for Renal Cell Carcinoma treatment, Visit @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Renal Cell Carcinoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Renal Cell Carcinoma Collaboration Deals
9. Late Stage Products (Phase III)
10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. IPI-549: Infinity Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AVB-S6-500: Aravive Inc.
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Renal Cell Carcinoma Key Companies
23. Renal Cell Carcinoma Key Products
24. Renal Cell Carcinoma - Unmet Needs
25. Renal Cell Carcinoma - Market Drivers and Barriers
26. Renal Cell Carcinoma - Future Perspectives and Conclusion
27. Renal Cell Carcinoma Analyst Views
28. Renal Cell Carcinoma Key Companies
29. Appendix
For further information on the Renal Cell Carcinoma pipeline therapeutics, reach out @ Renal Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Other Important Links-
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Vascular Grafts Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Acne Vulgaris Market- https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Angiofibroma Market- https://www.delveinsight.com/report-store/angiofibroma-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Ascites Market- https://www.delveinsight.com/report-store/ascites-market
Systemic Lupus Erythematosus Market- https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Cxcr Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Androgen Receptor Inhibitor Market- https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
STS Devices Market- https://www.delveinsight.com/report-store/sts-devices-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cell Carcinoma Pipeline Outlook, Clinical Trials and Emerging Drugs 2024 (Updated) here
News-ID: 3527867 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
